Pancreatic Cancer
Also known as: Pancreas, Pancreatic, Adenoma, Adenomatous, Tumor
Methodology & AI Transparency ⓘ
Pancreatic Cancer Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: The pancreas is a gland behind your stomach and in front of your spine.
- 2 Real-world patient consensus: Mapped to Cancer, Oncology & Supportive Care under ICD-10-CM C25.9 for Pancreatic Cancer clinical workups.
- 3 Typical cash cost range: Differential triage of Pancreatic Cancer (C25.9) utilizes radiation) paired with in Pancreatic Cancer (C25.9: proactive supportive symptom).
- 4 Top reported side effects / signs: Key Cancer & Oncology biomarkers for Pancreatic Cancer (C25.9): Complete Blood Count in Pancreatic Cancer (C25.9: (ANC, Hemoglobin, Platelets)) & Comprehensive Metabolic & in Pancreatic Cancer (C25.9: Organ Function Panel) (Preserved renal/hepatic clearance (C25.9)).
Ask our AI Specialists anything about Pancreatic Cancer
What Is Pancreatic Cancer?
The pancreas is a gland behind your stomach and in front of your spine. It produces the juices that help break down food and the hormones that help control blood sugar levels. Pancreatic cancer usually begins in the cells that produce the juices. Some risk factors for developing pancreatic cancer include: Smoking Long-term diabetes Chronic pancreatitis Certain hereditary disorders Pancreatic cancer is hard to catch early. It doesn't cause symptoms right away. When you do get symptoms, they are often vague or you may not notice them. They include yellowing of the skin and eyes, pain in the abdomen and back, weight loss and fatigue.
Pathophysiology, Underlying Causes & Clinical Presentation
Pancreatic Cancer (C25.9) alters cancer & oncology homeostasis through tumor-suppressor loss enabling in Pancreatic Cancer (C25.9: clonal proliferation); Cross-referenced with NIH MeSH (Pancreatic Neoplasms), clinical remission targets Comprehensive Metabolic & in Pancreatic Cancer (C25.9: Organ Function Panel) within Preserved renal/hepatic clearance (C25.9).
Common Symptoms & Clinical Signs
- • Long-term diabetes
- • Chronic pancreatitis
- • Presentation of Pancreatic Cancer (C25.9): unintended weight loss [Pancreatic Cancer C25.9]
- • Secondary Pancreatic Cancer clinical sign: unexplained bleeding, chronic in Pancreatic Cancer (C25.9: hoarseness/cough, or progressive)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Pancreatic Cancer Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C25.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Complete Blood Count in Pancreatic Cancer (C25.9: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C25.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Pancreatic Cancer (C25.9: Organ Function Panel) | Preserved renal/hepatic clearance (C25.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Pancreatic Cancer (C25.9: Genomic Staging) | Guideline-concordant surveillance (C25.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Pancreatic Cancer
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Pancrelipase Lipase, Pancrelipase Protease, Pancrelipase Amylase Zenpep • RxCUI 1594671 | FDA Prescription Therapeutic Agent | 86% | $4.1778 | $ 177.70 /mo |
| Pancrelipase Pertzye, Creon • RxCUI 1294122 | FDA Prescription Therapeutic Agent | 83% | $2.6645 | $ 116.41 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Pancreatic Cancer)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Postoperative Pain Treatment After Pancreatic: What a 1,468-Participant Study Found The available evidence was insufficient to establish the superiority of any single pain-relieving strategy after major pancreatic surgery. European journal of pain (London, England) • 2026-11-15 • Meta-Analysis | N = 1,468 | 99/100 | PMID 42944586 ↗ |
| Managing Advanced pancreatic cancer: Can Mistletoe extract Make a Real Difference? (What a 290-Person Study Found) Since no benefit was observed, there is no clinical reason to recommend mistletoe extract in patients with advanced pancreatic cancer. Palliative medicine • 2026-07-15 • Phase III Randomized Trial | N = 290 | 93/100 | PMID 42059487 ↗ |
| New Insights on Health-related quality of life scores of metastatic pancreatic cancer patients: What a 466-Participant Study Found This is the first study to systematically derive EORTC QLQ-C30 reference values for mPC. BMC cancer • 2022-05-20 • Phase III Randomized Trial | N = 466 | 93/100 | PMID 35596182 ↗ |
| Can This Approach Help? Inside the Latest Research on A Deep Prostate-specific Antigen Response to Darolutamide plus Androgen Darolutamide resulted in deep and durable PSA responses, regardless of baseline PSA. European urology oncology • 2025-10-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40846621 ↗ |
| Can This Approach Help? Inside the Latest Research on Subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet The glycaemic efficacy of GIP/GLP-1 receptor agonist tirzepatide in type 2 diabetes results from concurrent improvements in key components of diabetes pathophysiology, namely β-cell function, insulin sensitivity, and glucagon... The lancet. Diabetes & endocrinology • 2022-06-15 • Randomized Controlled Trial | N = 117 | 88/100 | PMID 35468322 ↗ |
Pancreatic Cancer Patient Community & “People Like Me” Threads
Filter Pancreatic Cancer community threads and patient logs by age, biological sex, dosage, and treatment duration.